Journal: Nutrition & Metabolism

Article Title: Evaluation of markers of beige adipocytes in white adipose tissue of the mouse

doi: 10.1186/s12986-016-0081-2

Figure Lengend Snippet: List or thermoregulatory or beige markers employed in this study and their function

Article Snippet: Primary antibodies were: anti-FGF21, AF3057, and anti-CD137, AF937 (R&D Systems, Minneapolis, MN), anti-P2RX5, sc-398682 (Santa Cruz Biotechnology, Dallas, TX), anti-beta-actin, sc-47778 (Santa Cruz, Dallas, TX), and anti-UCP1, ab10983, (abcam, Cambridge, MA).

Techniques: Marker

Journal: Nutrition & Metabolism

Article Title: Evaluation of markers of beige adipocytes in white adipose tissue of the mouse

doi: 10.1186/s12986-016-0081-2

Figure Lengend Snippet: List of primer/probe sets

Article Snippet: Primary antibodies were: anti-FGF21, AF3057, and anti-CD137, AF937 (R&D Systems, Minneapolis, MN), anti-P2RX5, sc-398682 (Santa Cruz Biotechnology, Dallas, TX), anti-beta-actin, sc-47778 (Santa Cruz, Dallas, TX), and anti-UCP1, ab10983, (abcam, Cambridge, MA).

Techniques:

Journal: Nutrition & Metabolism

Article Title: Evaluation of markers of beige adipocytes in white adipose tissue of the mouse

doi: 10.1186/s12986-016-0081-2

Figure Lengend Snippet: Markers of beige adipocytes in vitro . The transcripts for FGF21 a , P2RX5 b , PAT2 c , CITED1 d , CAR4 e , TBX1 f , CD137 g , and TMEM26 ( h ) were evaluated in white and beige adipocytes in culture treated with isoproterenol (+ Iso) or without (− Iso) for 6 hrs. before harvesting the cells. Transcripts were normalized to white – Iso. Values are means ± SEM ( n = 3). (*) different from white – Iso, (#) different from white + Iso, (+) different from beige + Iso, (@) different from beige – Iso, p ≤ 0.05, two way ANOVA followed by multiple comparisons using the Holm-Sidak method

Article Snippet: Primary antibodies were: anti-FGF21, AF3057, and anti-CD137, AF937 (R&D Systems, Minneapolis, MN), anti-P2RX5, sc-398682 (Santa Cruz Biotechnology, Dallas, TX), anti-beta-actin, sc-47778 (Santa Cruz, Dallas, TX), and anti-UCP1, ab10983, (abcam, Cambridge, MA).

Techniques: In Vitro

Journal: Nutrition & Metabolism

Article Title: Evaluation of markers of beige adipocytes in white adipose tissue of the mouse

doi: 10.1186/s12986-016-0081-2

Figure Lengend Snippet: Summary of beigeing criteria met by the thermoregulatory genes and putative beige markers when studied under in vitro and in vivo conditions

Article Snippet: Primary antibodies were: anti-FGF21, AF3057, and anti-CD137, AF937 (R&D Systems, Minneapolis, MN), anti-P2RX5, sc-398682 (Santa Cruz Biotechnology, Dallas, TX), anti-beta-actin, sc-47778 (Santa Cruz, Dallas, TX), and anti-UCP1, ab10983, (abcam, Cambridge, MA).

Techniques: In Vitro, In Vivo, Cell Culture

Journal: Nutrition & Metabolism

Article Title: Evaluation of markers of beige adipocytes in white adipose tissue of the mouse

doi: 10.1186/s12986-016-0081-2

Figure Lengend Snippet: Markers of beige adipocytes in inguinal adipose tissue. The transcripts for FGF21, P2RX5, PAT2, CITED1, CAR4, TBX1, CD137, and TMEM26 were evaluated in inguinal adipose tissue from mice maintained at room temperature (22 °C) or exposed to cold (5 °C) for one week in 3 separate experiments were the ages of the mice at the end of the experiment were 2 months and 10 days (Exp-1), 2 months and 23 days (Exp-2), and 4 months and 10 days (Exp-3). The levels of the transcripts at 5 °C were normalized to the transcript of the same gene at 22 °C. Values are means ± SEM ( n = 4–5). (*) different from 22 °C, p ≤ 0.05, two-tailed t-test

Article Snippet: Primary antibodies were: anti-FGF21, AF3057, and anti-CD137, AF937 (R&D Systems, Minneapolis, MN), anti-P2RX5, sc-398682 (Santa Cruz Biotechnology, Dallas, TX), anti-beta-actin, sc-47778 (Santa Cruz, Dallas, TX), and anti-UCP1, ab10983, (abcam, Cambridge, MA).

Techniques: Two Tailed Test

Journal: Nutrition & Metabolism

Article Title: Evaluation of markers of beige adipocytes in white adipose tissue of the mouse

doi: 10.1186/s12986-016-0081-2

Figure Lengend Snippet: Markers of beige adipocytes in the adipocyte and SVF derived from inguinal adipose tissue. The transcripts for FGF21 a , P2RX5 b , PAT2 c , CITED1 d , CAR4 e , TBX1 f , CD137 g , and TMEM26 ( h ) were evaluated in the adipocyte and SVF of 4 month old mice kept at room temperature (22 °C) or exposed to the cold (5 °C) for one week. Transcripts were normalized to 22 °C, SVF. Values are means ± SEM ( n = 3–5). (*) different from SVF 22 °C, (#) different from SVF 5 °C, (+) different from adipocytes 5 °C, (@) different from adipocytes 22 °C, p ≤ 0.05, two way ANOVA followed by multiple comparisons using the Holm-Sidak method

Article Snippet: Primary antibodies were: anti-FGF21, AF3057, and anti-CD137, AF937 (R&D Systems, Minneapolis, MN), anti-P2RX5, sc-398682 (Santa Cruz Biotechnology, Dallas, TX), anti-beta-actin, sc-47778 (Santa Cruz, Dallas, TX), and anti-UCP1, ab10983, (abcam, Cambridge, MA).

Techniques: Derivative Assay

Journal: Nutrition & Metabolism

Article Title: Evaluation of markers of beige adipocytes in white adipose tissue of the mouse

doi: 10.1186/s12986-016-0081-2

Figure Lengend Snippet: Beige markers in preadipocytes and SVF cells in vitro . The transcripts for CAR4, CITED1, PAT2, FGF21, P2RX5, CD137, TBX1, and TMEM26 were evaluated in SVF cells and beige adipocytes in culture. Transcripts were normalized to SVF cells. Values are means ± SEM ( n = 3). (*) different from SVF, p ≤ 0.05, two-tailed t-test

Article Snippet: Primary antibodies were: anti-FGF21, AF3057, and anti-CD137, AF937 (R&D Systems, Minneapolis, MN), anti-P2RX5, sc-398682 (Santa Cruz Biotechnology, Dallas, TX), anti-beta-actin, sc-47778 (Santa Cruz, Dallas, TX), and anti-UCP1, ab10983, (abcam, Cambridge, MA).

Techniques: In Vitro, Two Tailed Test

Journal: iScience

Article Title: The CIt protocol: A blueprint to potentiate the immunogenicity of immunoproteasome-reprogrammed mesenchymal stromal cells

doi: 10.1016/j.isci.2022.105537

Figure Lengend Snippet:

Article Snippet: InVivoPlus anti-mouse 4-1BB (CD137) , BioXCell , CAT# BP0239, RRID: AB_2924874.

Techniques: Recombinant, Saline, Enzyme-linked Immunosorbent Assay, Selection, Software

Journal: bioRxiv

Article Title: Basic-Leucine-Zipper Transcription Factors Regulate Selective Molecular Phenotypes in Regulatory T Cells During IL-2-Induced Activation

doi: 10.1101/2025.02.25.638325

Figure Lengend Snippet: (A) Percentage of live Treg cells that co-express ST2 and 4-1BB surface proteins compared to those that do not co-express them for each single gene knockout condition, where color filled circles represent means of technical triplicates and error bars represent standard deviations. (B) Percentage of live Treg cells that co-express ST2 and 4-1BB surface proteins compared to those that do not co-express them for each dual gene knockout condition, where color filled squares represent means of technical triplicates and error bars represent standard deviations. (C) Integrated Genomics Viewer (IGV) view of bulk ATAC-seq peaks comparing Fosl2 and Jund dual and Batf single gene knockout with the control at the Il1rl1 locus. (D) Integrated Genomics Viewer (IGV) view of bulk ATAC-seq peaks comparing Fosl2 and Jund dual and Batf single gene knockout with the control at the Sell locus.

Article Snippet: After two washes in PBS containing 2% FBS (#SH30071.03, Hyclone, GE Life Sciences), an antibody cocktail containing CD45-BV510 (#563891, BD Biosciences), CD4-BUV395 (#740208, BD Biosciences), CD25-PE (#553866, BD Biosciences), CD73-FITC (#567701, BD Biosciences), GITR-PE-Cy7 (#25-5874-82, Invitrogen), ST2-BV605 (#745257, BD Biosciences) and 4-1BB-AlexaFluor647 (#FAB937R, R&D Systems) were added to the cell suspension and incubated for 45 minutes on ice in the dark.

Techniques: Gene Knockout, Control

Journal: Signal transduction and targeted therapy

Article Title: Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma.

doi: 10.1038/s41392-024-02105-7

Figure Lengend Snippet: Fig. 4 PU.1 modulated PD-1/PD-L1 and 4-1BB/4-1BBL-mediated FL cell interaction with cDC1. a Immune checkpoints with differential expression between the cDC1 high and low groups identified by RNA sequencing. b Correlation between PU.1 and PD-L1, as well as PU.1 and 4-1BBL expression calculated by Pearson correlation coefficient analysis. c Relative luciferase activities in PD-L1 WT or PD-L1 MUT transfected HEK-293T cells, SC1 cells, DOHH2 cells were detected. Mean with SD was presented (n = 3). d Relative luciferase activities in 4-1BBL WT or 4-1BBL MUT transfected HEK-293T cells, SC1 cells, DOHH2 cells were detected. Mean with SD was presented (n = 3). e Western blot of PU.1, PD-L1, and 4-1BBL expression in the SpCas9-PU.1 transfected SC1 cells and pGMLV-PU.1 transfected DOHH2 cells

Article Snippet: For PD-L1 and 4-1BB antibody treatment, each mouse received an injection of 200 μg anti-mouse 4-1BB agonistic antibody (BE0296, Bioxcell, Lebanon, USA) and anti-mouse PD-L1 antibody (BE0101, Bioxcell) via the tail vein, three times each week for 2 weeks.

Techniques: Quantitative Proteomics, RNA Sequencing, Expressing, Luciferase, Transfection, Western Blot

Journal: Signal transduction and targeted therapy

Article Title: Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma.

doi: 10.1038/s41392-024-02105-7

Figure Lengend Snippet: Fig. 5 Dual targeting PD-L1 and 4-1BB counteracted PU.1-mediated cDC1 alterations in vitro. a Cell growth of the SpCas9-PU.1-transfected SC1 co-culture system, treated with or without the bi-specific PD-L1/4-1BB antibody assessed by MTT assay. Mean with SD was presented (n = 5). b cDC1 absolute cell numbers in the SpCas9-PU.1 transfected SC1 co-culture system treated with or without bi-specific PD-L1/4-1BB antibody assessed by flow cytometry. Mean with SD was presented (n = 3). c cDC1 maturation in the SpCas9-PU.1 transfected SC1 co-culture system treated with or without bi-specific PD-L1/4-1BB antibody assessed by flow cytometry. Mean with SD was presented (n = 3). d cDC1 endocytic activity in the SpCas9-PU.1 transfected SC1 co-culture system treated with or without bi-specific PD-L1/4-1BB antibody assessed by flow cytometry. Mean with SD was presented (n = 3). e LC3B expression in the SpCas9-PU.1 transfected SC1 co-culture system treated with or without bi-specific PD-L1/4-1BB antibody. Mean with SD was presented (n = 3). f Typical autophagosomes in the SpCas9-PU.1-transfected SC1 co-culture system, with or without bi-specific PD-L1/4-1BB antibody treatment assessed by transmission electron microscope. Cells were counted from randomly selected fields (n = 5). Mean with SD was presented

Article Snippet: For PD-L1 and 4-1BB antibody treatment, each mouse received an injection of 200 μg anti-mouse 4-1BB agonistic antibody (BE0296, Bioxcell, Lebanon, USA) and anti-mouse PD-L1 antibody (BE0101, Bioxcell) via the tail vein, three times each week for 2 weeks.

Techniques: In Vitro, Transfection, Co-Culture Assay, MTT Assay, Cytometry, Activity Assay, Expressing, Transmission Assay, Microscopy

Journal: Signal transduction and targeted therapy

Article Title: Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma.

doi: 10.1038/s41392-024-02105-7

Figure Lengend Snippet: Fig. 6 Combined treatment of PD-L1 and 4-1BB antibody exhibited in vivo anti-lymphoma activity on PU.1-altered murine xenograft model. a SpCas9-scramble and SpCas9-PU.1 cells were injected subcutaneously treated with or without lenalidomide, or co-treated with PD-L1 and 4-1BB antibody. Tumor size was measured. Mean with SD was presented (n = 3). b Standardized uptake value intensity in SpCas9-scramble group and SpCas9-PU.1 group treated with or without lenalidomide, or co-treated with PD-L1 and 4-1BB antibody assessed by Micro PET-CT. c, d cDC1 maturation in SpCas9-scramble group and SpCas9-PU.1 group treated with or without lenalidomide, or co-treated with PD-L1 and 4-1BB antibody assessed by flow cytometry. Mean with SD was presented (n = 3). e Flow cytometry analysis of cDC1 endocytic activity in SpCas9-scramble group and SpCas9-PU.1 group treated with or without lenalidomide, or co-treated with PD-L1 and 4-1BB antibody. Mean with SD was presented (n = 3). f Typical autophagosomes in the SpCas9-scramble group and SpCas9-PU.1 group, with or without lenalidomide treatment, or co-treated with PD-L1 and 4-1BB antibody assessed by transmission electron microscopy. Cells were counted from randomly selected fields (n = 5). Mean with SD was presented

Article Snippet: For PD-L1 and 4-1BB antibody treatment, each mouse received an injection of 200 μg anti-mouse 4-1BB agonistic antibody (BE0296, Bioxcell, Lebanon, USA) and anti-mouse PD-L1 antibody (BE0101, Bioxcell) via the tail vein, three times each week for 2 weeks.

Techniques: In Vivo, Activity Assay, Injection, Micro-PET, Cytometry, Flow Cytometry, Transmission Assay, Electron Microscopy